Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash & Equivalents (2016 - 2026)

Conmed filings provide 17 years of Cash & Equivalents readings, the most recent being $35.0 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 1.28% to $35.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $35.0 million, a 1.28% decrease, with the full-year FY2025 number at $40.8 million, up 66.88% from a year prior.
  • Cash & Equivalents hit $35.0 million in Q1 2026 for Conmed, down from $40.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $53.2 million in Q2 2022 to a low of $24.3 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $33.4 million (2022), compared with a mean of $32.9 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 47.61% in 2023 and later surged 66.88% in 2025.
  • Conmed's Cash & Equivalents stood at $28.9 million in 2022, then decreased by 16.05% to $24.3 million in 2023, then grew by 0.67% to $24.5 million in 2024, then surged by 66.88% to $40.8 million in 2025, then decreased by 14.18% to $35.0 million in 2026.
  • The last three reported values for Cash & Equivalents were $35.0 million (Q1 2026), $40.8 million (Q4 2025), and $38.9 million (Q3 2025) per Business Quant data.